<DOC>
	<DOCNO>NCT00818870</DOCNO>
	<brief_summary>The study design assess compare effect Vecam 40/300 , Vecam 20/300 Omeprazole 20 mg ( standard FDA approve GERD treatment ) control gastric pH .</brief_summary>
	<brief_title>Effect Vecam 40/300 Vecam 20/300 Compared Omeprazole 20 mg Gastric pH</brief_title>
	<detailed_description>Eligible H. pylorus negative , normal gastric acid secreting , healthy volunteer treat study medication randomize , open-label , cross-over study.Up 60 volunteer may enrol ensure least 30 subject complete study treatment . Omeprazole 20 mg administer breakfast . Vecam 40/300 Vecam 20/300 administer bedtime w/o food . 24-hour gastric pH measure fifth dose ( day 5 ) .Following screen procedure , subject randomly assign receive different treatment . All pH measurement do study center supervise condition . All drug administration supervise . This study part Vecam clinical development plan .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Healthy , H. pylori negative status ( Urea Breath Test ) Male female subject Age 1855 year Able tolerate placement nasogastric pH probe screen Baseline Gastric pHâ‰¤2 Use acceptable form birth control females childbearing potential Had use form tobacco ( e.g . smoke chew ) last year Can swallow size `` 00 '' capsule without difficulty Willing comply study protocol Signed Informed Consent form BMI &gt; 40 Slow poor Omeprazole metabolizers ( heterozygous homozygous , respectively ) base CYP2C19 genotyping test . Any significant history / concurrent gastrointestinal disease condition : GERD Acute gastrointestinal bleeding Zollinger Ellison Syndrome Gastric hypersecretory condition Known Barrett 's esophagus Esophageal stricture Peptic ulcer disease ( gastric duodenal ) family history peptic ulcer disease Gastric outlet obstruction Gastroparesis Significant medical history concurrent illness determine principal investigator Any medical disorder alters normal gastric acid secretion profile determine principal investigator History diabetes mellitus Significant laboratory abnormality determine principal investigator Known metabolic alkalosis , hypocalcemia , sodium restrict diet , hypokalemia , respiratory alkalosis Pregnant lactate woman Had treat investigational drug therapy participate clinical trial within 30 day prior enter trial Use medication contraception hormone replacement therapy ; OTC drug vitamins occasional acetaminophen within 30 day prior enter trial trial Use NSAID medication within 30 day prior enter trial ( e.g . Ibuprofen , Aspirin , Naproxen etc ) Positive urine test alcohol drug Concurrent use gastric antisecretory drug define : Use PPI 30 day prior stage trial Use H2RA 14 day prior stage trial Concurrent use antacid ( include overthecounter ) 24 hour prior stage trial Use medication modifies gastric acid secretion 30 day prior trial . Had ingest grapefruit within 14 day dose administration trial period Significant drug allergy know hypersensitivity ingredient trial drug Omeprazole , Succinic Acid Lidocaine Consumption coffee within 48 hour dose administration trial period . Had donate blood within 30 day enter trial Known positive serology HBV , HCV HIV Any reason make subject poor candidate base physician 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Gastroesophageal Reflux</keyword>
	<keyword>GERD</keyword>
	<keyword>Nocturnal GERD</keyword>
	<keyword>Heartburn</keyword>
	<keyword>Nighttime Heartburn</keyword>
	<keyword>Nocturnal Heartburn</keyword>
</DOC>